Advertisement
News
Advertisement

Gilead, Teva Settle Viread Suit

Wed, 02/20/2013 - 10:07am

Gilead Sciences Inc. announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

"We believe strongly in the validity of our intellectual property," said John Milligan, PhD, Gilead's President and Chief Operating Officer. "This settlement, however, removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation."

The trial in this litigation has been adjourned pending completion of activities necessary to finalize the settlement.

Date: February 20, 2013
Source: Gilead Sciences Inc.

Advertisement

Share This Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading